Back to search results

Observational Study for ALS and Other Motor Neuron Disorders

This study is collecting clinical information and blood samples from people with Amyotrophic Lateral Sclerosis (ALS) and their family members. The goal is to create a resource for future research into the genetic causes of ALS. Blood samples will also be collected from people without a personal or family history of ALS to serve as a comparison group. You may be able to join if you have ALS or suspected ALS, or if you are a blood relative (first, second, or third degree) of someone with a history of ALS. The study aims to enroll 3000 participants. The current recruitment status is unclear.

Study design
This is an observational study that plans to enroll 3000 participants. It is collecting data and samples for future research.
What's involved
Participants will provide clinical data and blood samples for DNA, RNA, lymphocytes, plasma, and serum extraction.
Compensation
Not stated in the trial record.
Follow-up
Blood collection is measured at 50 years, which may indicate a long-term follow-up period.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05474235

Studies in Amyotrophic Lateral Sclerosis (ALS) and Other Neurodegenerative Motor Neuron Disorders

Recruiting
Not specifiedAges 18+Observational
Mayo Clinic
~3,000 participants
Updated 2026-08-27 on ClinicalTrials.gov

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Blood Collection
Measured over 50 years

Conditions

Amyotrophic Lateral Sclerosis

Explore related trials

Amyotrophic Lateral Sclerosis

NCT05474235

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Mayo Clinic Florida

    Jacksonville, Floridastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Bjorn Oskarsson, MD · PRINCIPAL_INVESTIGATOR · Mayo Clinic

Who to contact

Chris Liriano
[email protected]
904-953-5325
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Clinical diagnosis of possible, laboratory-supported probable, probable or definite ALS according to modified EL Escorial criteria, suspected ALS according to original El Escorial criteria, or diagnosis of a neurodegenerative disorder with evidence of ALS plus extramotor features; OR
Blood relative (first, second or third degree) with history of ALS or neurodegenerative disorder with evidence of ALS plus extramotor features; OR:
A clinical suspicion or referral for ALS;
\> 18 years of age;
Willing and able to give signed informed consent or assent that has been approved by the Institutional Review Board (IRB).
Family history (first, second or third degree blood relative) of ALS or other motor neuron disease;
\> 18 years of age;
Willing and able to give signed informed consent that has been approved by the Institutional Review Board (IRB).
No personal or family history (first, second or third degree blood relative) of ALS or other motor neuron disease;
\> 18 years of age;
No personal history of other neurodegenerative disease (i.e., Alzheimer disease, Parkinson disease);
Willing and able to give signed informed consent that has been approved by the Institutional Review Board (IRB).

Exclusion

Personal or family history of dementia or other neurodegenerative disease (Parkinson disease, Alzheimer disease, etc.);
Limited mental capacity rendering the subject unable to provide written informed consent or comply with standard phlebotomy procedures.

What this trial measures

  • Blood Collection50 years

    Total number of blood samples collected